Purchase Order 75F40121P00263
Award Date 6/15/21
Potential Completion Date 7/15/26
Potential Value $458K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Other Statutory Authority
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of genomic sequencing instruments and reagents, for the provision of a next generation sequencer. The contract has a potential value of $100,980.00 and a completion date of August 28, 2020. Illumina has provided similar sequencing systems and consumables to support genomic research and diagnostics across various federal agencies such as the National...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The $114,681.00 contract is for the delivery of a MiSeq System, a high-throughput next-generation DNA sequencing platform used to support life science research, applied markets, and molecular diagnostics. This award does not have a set-aside designation. Illumina has a history of providing...
- The Department of Health and Human Services Food and Drug Administration awarded a $533,378 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for delivery of one Illumina NextSeq 2000 Sequencing System to support the agency's microbial metagenomics research in Berwyn Heights, Maryland. The original solicitation requested an integrated genomic sequencing system, including the NextSeq 2000 or equivalent, to generate sequence data, perform real-time...
- This firm fixed-price purchase order contract was awarded by the Food and Drug Administration (FDA), a civilian agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing technologies. The $576,928.00 contract is for the procurement of an Illumina NextSeq2000 Sequencing System, including associated reagents and maintenance services. The contract has a period of performance through July 20, 2026. Illumina is a key technology provider for federal scientific and diagnostic...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of genomic sequencing instruments and reagents, for the delivery of 3 Illumina MiSeq sequencing systems. The $284,971.50 contract has an April 30, 2019 completion date and does not use any set-aside provisions. Illumina has a history of providing sequencing equipment and consumables to support genomic research and diagnostics at various federal...
- The Department of Health and Human Services Food and Drug Administration awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of genomic sequencing instruments and related products, for the provision of a MiSeq sequencing instrument and a one-year preventative maintenance agreement. The total potential value of this contract is $109,857.00. Illumina has a history of providing sequencing systems and services to support genomic research and diagnostics across various federal...
- The Department of Health and Human Services Food and Drug Administration awarded a $534,031 firm fixed price purchase order to Illumina, Inc. of San Diego, California. The contract is for an Illumina NextSeq 2000 High Throughput Next-Generation Sequencing System to be delivered to Silver Spring, Maryland. The solicitation notice indicated the FDA requires this sequencing system to adapt standard operating procedures for its currently installed Illumina NextSeq 500 model, scale up sequencing...
- The Department of Health and Human Services Food and Drug Administration awarded a $169,505.48 firm fixed price purchase order to Illumina, Inc. of Laurel, Maryland for an Illumina NextSeq 50 System Check. The contract has a period of performance through February 10, 2025 to deliver product care services for the NextSeq 50 sequencing system. No set-aside provisions were applied to this award made by the FDA to support its regulatory and public health responsibilities through genomic analysis...
- This contract is for the acquisition of the NEXTSEQ 2000 SEQUENCING SYSTEM by the Department of Health and Human Services Food and Drug Administration. The $432,031.00 firm fixed price contract was awarded to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract has a completion date of November 12, 2025 and does not have a set-aside designation. Illumina has previously been awarded prime contracts by federal agencies such as the...
- The U.S. Food and Drug Administration awarded a $219,300 firm fixed price purchase order to Illumina, Inc. for a NextSeq 2000 Sequencing System. This award was not subject to any set-aside provisions. Illumina is a manufacturer of sequencing and genomic analysis instruments and reagents that has been awarded past federal contracts with agencies such as the NIH, CDC, USDA, and VA to provide a range of sequencing systems and related products. The award references an original small business...